Legend Biotech’s carvykti improves overall survival in Phase 3 myeloma trial

Legend Biotech announced positive overall survival results from CARTITUDE-4, an ongoing, global randomized, open-label Phase 3 study evaluating the efficacy and safety of carvykti versus pomalidomide, bortezomib and dexamethasone or daratumumab, pomalidomide, and dexamethasone in adult patients with relapsed and lenalidomide-refractory multiple myeloma who received one to three prior lines of therapy. In the second interim analysis of the trial, carvykti demonstrated statistically significant and clinically meaningful improvement in overall survival. Safety results were consistent with the established safety profile of carvykti, and no new safety signals were identified. These new results will be presented at an upcoming medical meeting and shared with regulatory agencies for label updates worldwide. Data from CARTITUDE-4 supported the FDA approval of carvykti on April 5 for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy and are refractory to lenalidomide.